Has Jorge Garcia, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,735,070 in general payments to Jorge Garcia, MD across 506 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jorge Garcia, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jorge Garcia, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jorge Garcia, MD

Hematology & Oncology · Cleveland, OHNPI 1770688913

Payments from drug & device makers

$1,735,070in general payments, 2019–2025

Across 506 payments — averaging $3428.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$493K
Janssen Research & Development, LLC$251K
Pfizer$229K
Merck$205K
Bayer$98K
Genentech, Inc.$60K
plus $399K from 39 others

$2,000in research payments, 2019–2025

Across 2 payments — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	16	$492,964
Janssen Research & Development, LLC	23	$251,409
Pfizer	33	$228,990
Merck	59	$204,970
Bayer	111	$98,476
Genentech, Inc.	6	$59,678
Sanofi	31	$53,009
Clovis Oncology, Inc.	22	$49,369
E.r. Squibb & Sons, L.L.C.	2	$36,217
Astellas Pharma US Inc	20	$30,839
Johnson & Johnson	41	$30,484
Eli Lilly	5	$30,329
Sun Pharmaceutical Industries Inc.	22	$28,425
Amgen	9	$17,026
GSK	1	$16,470
Urogen Pharma, Inc.	5	$15,665
Eisai Inc.	16	$15,604
Astrazeneca UK Limited	1	$14,640
Astellas Pharma Global Development	8	$12,829
Acrotech Biopharma Inc.	1	$10,800
Beigene USA, Inc.	1	$9,608
Advanced Accelerator Applications	5	$9,379
Bristol Myers Squibb(2 entities)	3	$8,573
Alkermes, Inc.	1	$7,000
LEO Pharma Inc.	22	$449
Sumitomo Pharma America, Inc.	4	$327
Organon	2	$259
AstraZeneca	2	$202
AbbVie	8	$155
Novartis	1	$140
Coherus Oncology, Inc.	1	$130
Janssen Scientific Affairs, LLC	1	$125
Myovant Sciences Inc.	1	$94
UCB, Inc.	4	$61
Dermavant Sciences, Inc.	3	$60
Convatec Inc.	2	$57
Takeda Pharmaceuticals U.S.A., Inc.	1	$46
Telix Pharmaceuticals	1	$40
Ortho Dermatologics, A Division Of Bausch Health US, LLC	3	$39
DUSA Pharmaceuticals, Inc.	2	$33
Almirall LLC	2	$28
Regeneron Healthcare Solutions, Inc.	1	$21
Gilead	1	$21
Verrica Pharmaceuticals Inc.	1	$17
Springworks Therapeutics, Inc.	1	$14

How this compares

$1,735,070 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Medicare billing

Part B allowed, 2024

$25,253

Medicare patients

119

Services billed

308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Cleveland

Afshin DowlatiCleveland$25.1M
Brian HillCleveland$11.6M
Christopher HoimesCleveland$7.5M
Balazs HalmosCleveland$7M
Dale ShepardCleveland$5.1M
Paolo CaimiCleveland$4.2M
Allison WinterCleveland$4.2M
Nathan PennellCleveland$3.8M
Ankit ManglaCleveland$3.3M
David BajorCleveland$3.3M

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →